Promising cancer drug study halted early: what happened?
Disease control
Terminated
This study tested a drug called Promitil in 19 people with ovarian or pancreatic cancer that had specific genetic changes (BRCA or HRD mutations) and had stopped responding to first treatment. The goal was to see if Promitil could slow or stop cancer growth. The study was ended e…
Phase: PHASE2 • Sponsor: Lipomedix Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 02:56 UTC